THIS SUPPLEMENTAL CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this supplemental circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this supplemental circular.

If you are in any doubt as to any aspect of this supplemental circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **Shanghai HeartCare Medical Technology Corporation Limited**, you should at once hand this supplemental circular with the enclosed Revised Proxy Form to the purchaser or the transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Shanghai HeartCare Medical Technology Corporation Limited

上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

SUPPLEMENTAL CIRCULAR
PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS AND SUPPLEMENTAL NOTICE OF THE POSTPONED 2026 THIRD EXTRAORDINARY GENERAL MEETING

Capitalized terms used in this cover page shall have the same meanings as defined in this supplemental circular.

This supplemental circular should be read together with the Original Circular of the Company dated October 29, 2026. A notice convening the original EGM to be held at Sealmedical Hall, 4/F, Building 8, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC at 10:00 a.m. on Friday, November 13, 2026 is set out on pages 20 to 22 of the Original Circular. A supplemental notice convening the Postponed EGM which has been postponed and rescheduled to 10:00 a.m. on Thursday, November 26, 2026 at Sealmedical Hall, 4/F, Building 8, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC is set out on pages 9 to 12 of this supplemental circular. A Revised Proxy Form for use at the Postponed EGM is enclosed and is also published on the websites of the Hong Kong Stock Exchange (www.hkexnews.hk) and the Company (www.heartcare.com.cn).

Shareholders who intend to appoint a proxy to attend the Postponed EGM shall complete and return the Revised Proxy Form in accordance with the instructions printed thereon not less than 24 hours before the time appointed for the Postponed EGM (i.e. no later than 10:00 a.m. on Wednesday, November 25, 2026) or any adjournment thereof (as the case may be). Completion and return of the Revised Proxy Form will not prevent you from attending and voting in person at the Postponed EGM or any adjournment thereof should you so wish.

For the avoidance of doubt and for the purpose of the Hong Kong Stock Exchange, holders of treasury Shares, if any, shall abstain from voting at the Postponed EGM.

Reference to times and dates in this supplemental circular are to Hong Kong local time and dates.

November 11, 2026

CONTENTS

Page

DEFINITIONS 1

LETTER FROM THE BOARD 3

SUPPLEMENTAL NOTICE OF THE POSTPONED 2026 THIRD EXTRAORDINARY GENERAL MEETING 9

In this supplemental circular, the following expressions shall have the meanings set out below unless the context requires otherwise:

"Announcement"	the announcement of the Company dated November 9, 2026 in relation to, among others, the postponement of the EGM
"Articles of Association" or "Articles"	the articles of association of the Company, as amended from time to time
"Company"	Shanghai HeartCare Medical Technology Corporation Limited (上海心瑋醫療科技股份有限公司), a joint stock limited liability company incorporated in the PRC, whose H Shares are listed on the Hong Kong Stock Exchange (Stock Code: 6609)
"EGM"	the 2026 third extraordinary general meeting of the Company which was originally scheduled to be held on November 13, 2026 as set out in the Original Notice
"Latest Practicable Date"	November 10, 2026, being the latest practicable date for the purpose of ascertaining certain information contained in this supplemental circular prior to its publication
"Original Circular"	the circular of the Company dated October 29, 2026 in respect of the matters to be considered at the EGM
"Original Notice"	the notice of the EGM as set out on pages 20 to 22 of the Original Circular
"Original Proxy Form"	the proxy form which was published on October 29, 2026 together with the Original Circular
"Postponed EGM"	the postponed 2026 third extraordinary general meeting of the Company which has been postponed and rescheduled to 10:00 a.m. on Thursday, November 26, 2026 at Sealmedical Hall, 4/F, Building 8, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC as set out in the Supplemental Notice

"Revised Proxy Form"	the revised proxy form which will be published on the websites of the Hong Kong Stock Exchange and the Company and despatched (if needed) together with this supplemental circular
"Shareholder(s)"	holder(s) of the Share(s)
"Supplemental Notice"	the notice of the Postponed EGM as set out on pages 9 to 12 of this supplemental circular

Shanghai HeartCare Medical Technology Corporation Limited
上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

Executive Directors:
Mr. WANG Guohui *(Chairman)*
Ms. ZHANG Kun
Mr. WEI Jiawei

Non-executive Directors:
Mr. CHEN Shaoxiong
Mr. CHEN Gang

Independent Non-executive Directors:
Mr. GUO Shaomu
Mr. FENG Xiangqian
Mr. GONG Ping

Registered office and headquarters in the PRC:
Building 38
No. 356, Zhengbo Road
Lingang New District
Pilot Free Trade Zone
Shanghai, PRC

Principal place of business in Hong Kong:
Room 1901, 19/F
Lee Garden One
33 Hysan Avenue
Causeway Bay
Hong Kong

November 11, 2026

To the Shareholders

Dear Sir/Madam,

SUPPLEMENTAL CIRCULAR
PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS AND SUPPLEMENTAL NOTICE OF THE POSTPONED 2026 THIRD EXTRAORDINARY GENERAL MEETING

I. INTRODUCTION

Reference is made to the Announcement. This supplemental circular should be read together with the Original Circular and the Original Notice. Unless otherwise defined, capitalized terms used in this supplemental circular shall have the same meanings as those defined in the Original Circular.

The purpose of this supplemental circular is to give you the Supplemental Notice and to provide you with further information regarding the resolution to be proposed at the Postponed EGM for approving the election of an executive Director to enable the Shareholders to make an informed decision on whether to vote for or against such resolution.

II. PROPOSED ELECTION OF AN EXECUTIVE DIRECTOR

Subsequent to the publication of the Original Circular, Mr. CHEN Gang ("**Mr. Chen**") has notified the Company that he intends to retire from his role as a non-executive Director of the Company and does not seek to be re-elected as a non-executive Director due to his other work arrangements at the upcoming Postponed EGM upon which a new session of the Board is due to be elected. Mr. Chen will also cease to be a member of the strategy committee of the Board upon his retirement as a non-executive Director.

Mr. Chen has confirmed that he has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of Hong Kong Stock Exchange and the Shareholders.

Upon receiving Mr. Chen's notification to retire from the Board, on November 9, 2026, the Board proposed to appoint Mr. ZHANG Han ("**Mr. Zhang**"), the Company's senior vice president, chief operating officer, chief financial officer, board secretary and a joint company secretary, as an executive Director and as a member of the strategy committee of the Board. Upon the proposed appointment of Mr. Zhang being approved by the Shareholders at the Postponed EGM, he will enter into a service contract with the Company for a term of three (3) years commencing from the date of approval at the Postponed EGM and shall then be eligible for re-election pursuant to the Articles of Association.

III. BIOGRAPHICAL DETAILS OF MR. ZHANG

Mr. Zhang, aged 39, as the senior vice president, chief operating officer, chief financial officer, board secretary and a joint company secretary of our Company, mainly responsible for taking the lead in the Company's strategic execution work, assisting the Chairman in coordinating the daily operation and management of the enterprise, as well as the Company's financial compliance, investment and financing, and market value management. Mr. Zhang joined our Company in November 2020 and appointed as the senior vice president, chief financial officer and board secretary on November 23, 2020. He was appointed as our company secretary on December 22, 2020 and was further appointed as our chief operating officer in March 2025. Mr. Zhang serves as a supervisor of two wholly-owned subsidiaries of our Company, namely Nanjing Sealmedical

Technology Co., Ltd. (南京思脈德醫療科技有限公司) and Weiming (Shanghai) Medical Device Co., Ltd. (瑋銘醫療器械(上海)有限公司), and he also holds various directorship roles with subsidiaries of the Group.

Mr. Zhang has extensive experience in equity capital market and financial management. Mr. Zhang started to work at Ernst & Young Hua Ming LLP (安永華明會計師事務所(特殊普通合夥)) in December 2009 and left as a senior associate in June 2012. From June 2012 to November 2020, he served as a senior manager, a director and an executive director of investment banking at Sinolink Securities Corporation Limited (國金證券股份有限公司), where he was responsible for the corporate finance and M&A business in healthcare sector.

Mr. Zhang obtained his bachelor's degree in accounting and international economic law from Shanghai University of Finance and Economics (上海財經大學) in the PRC in July 2009, and a master of business administration from China Europe International Business School (中歐國際工商學院) in November 2024. He is a member of CICPA since March 2014 and also a member of Certified Public Accountants Association of Australia since June 2012.

It is proposed that Mr. Zhang's remuneration shall be determined by the existing remuneration package of his positions at the Company, and he shall not be entitled to any additional remuneration for serving as an executive Director of the Company.

As of the Latest Practicable Date, Mr. Zhang holds 1,000,000 Unlisted Shares of the Company, representing approximately 12.09% of the outstanding issued Unlisted Shares of the Company, he also holds 72,000 H Shares of the Company and is interested in 168,000 unvested H Shares granted to him under the Company's 2025 H Share Incentive Scheme, which in aggregate represents 0.79% of the outstanding H Shares of the Company (excluding any treasury Shares). The above shares in aggregate represent 3.19% of the total issued Shares of the Company (excluding any treasury Shares).

Save as disclosed in this supplemental circular, as at the Latest Practicable Date, Mr. Zhang: (i) did not have any other relationship with any other director, senior management or substantial or controlling shareholders of the Company (within the definition of the Listing Rules); (ii) did not have any interests in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance; (iii) did not hold any other position with any member of the Group; (iv) had not held any directorship in any other companies listed in Hong Kong or overseas in the last three years; (v) had no other major appointment or professional qualification; and (vi) had no information that is required to be disclosed pursuant to Rules 13.51(2) of the Listing Rules nor any other matter that needs to be brought to the attention of the shareholders of the Company.

IV. SUPPLEMENTAL NOTICE OF THE POSTPONED EGM AND REVISED PROXY FORM

As disclosed in the Announcement, due to the additional resolution to be submitted to the Shareholders for their consideration and the additional time required by the Company to prepare for the relevant resolution, the Board has resolved to postpone the EGM originally scheduled at Sealmedical Hall, 4/F, Building 8, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC at 10:00 a.m. on Friday, November 13, 2026. The Postponed EGM will be held on 10:00 a.m. on Thursday, November 26, 2026 at Sealmedical Hall, 4/F, Building 8, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC to approve, among other things, the election of Mr. Zhang as an executive Director to the third session of the Board by way of an ordinary resolution.

Since the Original Notice and the Original Proxy Form published together with the Original Circular do not contain the proposed resolution in relation to the election of Mr. Zhang as an executive Director as set out in this supplemental circular, the Revised Proxy Form is enclosed with this supplemental circular to include such proposed resolution and withdraw the original resolution for the re-election of Mr. Chen as a non-executive Director. The Revised Proxy Form is also published on the websites of the Stock Exchange and the Company.

A Shareholder who has not yet lodged the Original Proxy Form with the Company's H Share registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (in case of holders of H Shares) or the Company's headquarters at Building 38, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC (in case of holders of Unlisted Shares) is requested to lodge the Revised Proxy Form if he/ she wishes to appoint proxies to attend and vote at the Postponed EGM on his/her behalf. In this case, the Original Proxy Form should not be lodged with the Company's H Share registrar or the Company's headquarters.

A Shareholder who has already lodged the Original Proxy Form with the Company's H Share registrar in Hong Kong or the Company's headquarters (as the case might be) should note that:

(i) If no Revised Proxy Form is lodged with the Company's H Share registrar in Hong Kong or the Company's headquarters (as the case might be), the Original Proxy Form, if correctly completed, will be treated as a valid proxy form lodged by him/her. The proxy so appointed by the Shareholder will be entitled to cast the vote at his/her discretion or to abstain from voting on any resolution properly put to the Postponed EGM (including, if properly put, a resolution for the election of Mr. Zhang as an executive Director as set out in this supplemental circular) except for the resolutions to which the Shareholder has indicated his/her voting direction in the Original Proxy Form.

(ii) If the Revised Proxy Form is lodged with the Company's H Share registrar in Hong Kong or the Company's headquarters (as the case might be) not less than 24 hours before the time appointed for the holding of the Postponed EGM (i.e. at or before 10:00 a.m. on Wednesday, November 25, 2026 (Hong Kong time)) or any adjourned meeting, the Revised Proxy Form, if correctly completed, will revoke and supersede the Original Proxy Form previously lodged by him/ her. The Revised Proxy Form will be treated as a valid proxy form lodged by the Shareholder.

(iii) If the Revised Proxy Form is lodged with the Company's H Share registrar in Hong Kong or the Company's headquarters (as the case might be) less than 24 hours before the time appointed for the holding of the Postponed EGM (i.e. at or after 10:00 a.m. on Wednesday, November 25, 2026 (Hong Kong time)) or any adjourned meeting, or if lodged not less than 24 hours before the time appointed for the holding of the Postponed EGM (i.e. at or before 10:00 a.m. on Wednesday, November 25, 2026 (Hong Kong time)) or any adjourned meeting but is incorrectly completed, the proxy appointment under the Revised Proxy Form will be invalid. The proxy so appointed by the Shareholder under the Original Proxy Form, if correctly completed, will be entitled to vote in the manner as mentioned in (i) above as if no Revised Proxy Form was lodged with the Company's H Share registrar in Hong Kong or the Company's headquarters (as the case might be). Accordingly, Shareholders are advised to complete the Revised Proxy Form carefully and lodge the Revised Proxy Form with the Company's H Share registrar in Hong Kong or the Company's headquarters (as the case might be) by not less than 24 hours before the time appointed for the holding of the Postponed EGM (i.e. at or before 10:00 a.m. on Wednesday, November 25, 2026 (Hong Kong time)) or any adjourned meeting.

Shareholders are reminded that submission of the Original Proxy Form and/or the Revised Proxy Form shall not preclude the Shareholders from attending the Postponed EGM or any adjourned meeting thereof and voting in person should they so wish.

In accordance with Rule 13.39(4) of the Hong Kong Listing Rules, any vote of the Shareholders at a general must be taken by poll. As such, all the resolutions set out in the Supplemental Notice convening the Postponed EGM will be voted by poll. Save as disclosed in this supplemental circular, if any, no Shareholder will have a material interest in the matters to be approved and will be required to abstain from voting in respect of such resolutions.

V. REVISED DATE OF CLOSURE OF H SHARE REGISTER OF MEMBERS

As set out in the Original Circular, the register of members of the Company is originally scheduled to be closed from Tuesday, November 10, 2026 to Friday, November 13, 2026, both days inclusive, during which period no transfer of shares of the Company will be registered, in order to determine the identity of the Shareholders who are entitled to attend and vote at the EGM.

Due to the postponement of the EGM, the period during which the register of members will be closed in order to determine the identity of the Shareholders who are entitled to attend and vote at the Postponed EGM (during which period no share transfers will be registered) will also be changed. The revised book closure period will be from Monday, November 23, 2026 to Thursday, November 26, 2026, both days inclusive, during which period no transfer of shares will be effected. In order to be eligible for attending and voting at the Postponed EGM, all transfers documents of H Shares accompanied by the relevant share certificates must be lodged with the Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Friday, November 20, 2026 for registration.

VI. RESPONSIBILITY STATEMENT

This supplemental circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this supplemental circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this supplemental circular misleading.

VII. RECOMMENDATION

The Directors (including the independent non-executive Directors) consider that all the resolutions as set out in the Supplemental Notice are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Board recommends all the Shareholders to vote in favour of all the resolutions as set out in the Supplemental Notice to be proposed at the Postponed EGM.

Shareholders are advised to read this supplemental circular together with the Original Circular for information relating to the voting arrangement.

By Order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai HeartCare Medical Technology Corporation Limited

上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

SUPPLEMENTAL NOTICE OF THE POSTPONED 2026 THIRD EXTRAORDINARY GENERAL MEETING

References are made to the circular (the "**Original Circular**") of Shanghai HeartCare Medical Technology Corporation Limited (the "**Company**") and the notice of the 2026 third extraordinary general meeting of the Company (the "**Original Notice**") both dated October 29, 2026, and the announcement of the Company dated November 9, 2026, in relation to, among other things, the postponement of the 2026 third extraordinary general meeting of the Company. This supplemental notice should be read together with the Original Notice.

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that the postponed 2026 third extraordinary general meeting (the "**Postponed EGM**") of the Company (together with its subsidiaries, the "**Group**") will be held at Sealmedical Hall, 4/F, Building 8, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC on Thursday, November 26, 2026 at 10:00 a.m. for the purpose of considering, and if thought fit, passing the following resolutions. Unless otherwise defined, capitalized terms used in this supplemental notice shall have the same meanings as those defined in the supplemental circular of the Company dated November 11, 2026 (the "**Supplemental Circular**").

ORDINARY RESOLUTIONS

1. To consider and approve the re-election and appointment of Mr. WANG Guohui as an executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the Postponed EGM, and he shall receive remuneration in accordance with the relevant policies and the unified standards set by the Company.

2. To consider and approve the re-election and appointment of Ms. ZHANG Kun as an executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the Postponed EGM, and she shall receive remuneration in accordance with the relevant policies and the unified standards set by the Company.

3. To consider and approve the re-election and appointment of Mr. WEI Jiawei as an executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the Postponed EGM, and he shall receive remuneration in accordance with the relevant policies and the unified standards set by the Company.

4. To consider and approve the election and appointment of Mr. ZHANG Han as an executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the Postponed EGM, and he shall receive remuneration in accordance with the relevant policies and the unified standards set by the Company.

5. To consider and approve the re-election and appointment of Mr. CHEN Shaoxiong as a non-executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the Postponed EGM, and he shall receive a fixed remuneration of RMB120,000 per year (before tax).

6. To consider and approve the election and appointment of Mr. LU Xubo as a non-executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the Postponed EGM, and he shall receive a fixed remuneration of RMB120,000 per year (before tax).

7. To consider and approve the re-election and appointment of Mr. GUO Shaomu as an independent non-executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the Postponed EGM, and he shall receive a fixed remuneration of HKD260,000 per year (before tax).

8. To consider and approve the re-election and appointment of Mr. FENG Xiangqian as an independent non-executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the Postponed EGM, and he shall receive a fixed remuneration of HKD220,000 per year (before tax).

9. To consider and approve the re-election and appointment of Mr. GONG Ping as an independent non-executive Director of the Third Session of the Board for a term of three (3) years commencing from the date of approval at the Postponed EGM, and he shall receive a fixed remuneration of RMB200,000 per year (before tax).

By Order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai, November 11, 2026

Notes:

1. A revised form of proxy (the "**Revised Proxy Form**") containing all the proposed resolutions to be considered at the Postponed EGM, including the revised ordinary resolution number 4 is enclosed with the Supplemental Circular. Please refer to the section headed "IV. SUPPLEMENTAL NOTICE OF THE POSTPONED EGM AND REVISED PROXY FORM" on the Supplemental Circular for arrangements on the completion and submission of the Revised Proxy Form.

2. Any Shareholder of the Company entitled to attend and vote at the Postponed EGM is entitled to appoint one or more proxies to attend and, on a poll, vote instead of him/her. A proxy need not be a member of the Company.

3. The instrument appointing a proxy shall be in writing under the hand of the appointer or of his/her attorney duly authorized in writing or, if the appointer is a corporation, either under its seal or under the hand of any officer or attorney duly authorized.

4. In order to be valid, the Revised Proxy Form together with the power of attorney or other authority, if any, under which it is signed or a notarially certified copy of such power or authority, must be deposited with Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for holders of H Shares) or the Company's registered office at Building 38, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC (for holders of Unlisted Shares) as soon as practicable but in any event not less than 24 hours before the time appointed for holding the Postponed EGM (i.e., at or before 10:00 a.m. on Wednesday, November 25, 2026 (Hong Kong Time)), or any adjourned meeting thereof (as the case may be).

   A Shareholder who has already lodged the Original Proxy Form with the Company's H Share registrar in Hong Kong or the Company's headquarters (as the case might be) should note that:

   (i) If no Revised Proxy Form is lodged with the Company's H Share registrar in Hong Kong or the Company's headquarters (as the case might be), the Original Proxy Form, if correctly completed, will be treated as a valid proxy form lodged by him/her. The proxy so appointed by the Shareholder will be entitled to cast the vote at his/her discretion or to abstain from voting on any resolution properly put to the Postponed EGM (including, if properly put, a resolution for the election of Mr. Zhang as an executive Director as set out in this supplemental circular) except for the resolutions to which the Shareholder has indicated his/her voting direction in the Original Proxy Form.

(ii) If the Revised Proxy Form is lodged with the Company's H Share registrar in Hong Kong or the Company's headquarters (as the case might be) not less than 24 hours before the time appointed for the holding of the Postponed EGM (i.e. at or before 10:00 a.m. on Wednesday, November 25, 2026 (Hong Kong time)) or any adjourned meeting, the Revised Proxy Form, if correctly completed, will revoke and supersede the Original Proxy Form previously lodged by him/her. The Revised Proxy Form will be treated as a valid proxy form lodged by the Shareholder.

(iii) If the Revised Proxy Form is lodged with the Company's H Share registrar in Hong Kong or the Company's headquarters (as the case might be) less than 24 hours before the time appointed for the holding of the Postponed EGM (i.e. at or after 10:00 a.m. on Wednesday, November 25, 2026 (Hong Kong time)) or any adjourned meeting, or if lodged not less than 24 hours before the time appointed for the holding of the Postponed EGM (i.e. at or before 10:00 a.m. on Wednesday, November 25, 2026 (Hong Kong time)) or any adjourned meeting but is incorrectly completed, the proxy appointment under the Revised Proxy Form will be invalid. The proxy so appointed by the Shareholder under the Original Proxy Form, if correctly completed, will be entitled to vote in the manner as mentioned in (i) above as if no Revised Proxy Form was lodged with the Company's H Share registrar in Hong Kong or the Company's headquarters (as the case might be). Accordingly, Shareholders are advised to complete the Revised Proxy Form carefully and lodge the Revised Proxy Form with the Company's H Share registrar in Hong Kong or the Company's headquarters (as the case might be) by not less than 24 hours before the time appointed for the holding of the Postponed EGM (i.e. at or before 10:00 a.m. on Wednesday, November 25, 2026 (Hong Kong time)) or any adjourned meeting.

5. Completion and return of the Original Proxy Form and/or the Revised Proxy Form shall not preclude the Shareholders of the Company from attending and voting in person at the Postponed EGM or at any adjourned meeting thereof (as the case may be) should they so wish, and in such event, the form of proxy shall be deemed to be revoked.

6. Where there are joint registered holders of any share, any one of such joint holders may vote, either in person or by proxy, in respect of such share as if he/she was solely entitled thereto, but if more than one of such joint holders are present at the Postponed EGM, whether in person or by proxy, the joint registered holder present whose name stands first on the register of members of the Company in respect of the shares shall alone be entitled to vote in respect thereof.

7. For the purpose of determining the Shareholders of the Company entitled to attend and vote at the Postponed EGM, the register of members of the Company will be closed from Monday, November 23, 2026 to Thursday, November 26, 2026 (both days inclusive). The record date for determining the entitlement of the Shareholders of the Company to attend and vote at the Postponed EGM will be November 26, 2026. In order to qualify for the entitlement to attend and vote at the above Postponed EGM, H Shareholders must lodge all transfer forms accompanied by the relevant H Share certificates with the Company's H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong by no later than 4:30 p.m. on Friday, November 20, 2026.

8. The Postponed EGM is expected to take less than half a day. Shareholders who attend the Postponed EGM shall be responsible for their own travel and accommodation expenses. Shareholders may contact the Investor Relations Department of the Company at +86 21 5897 5056 or ir@heartcare.com.cn for any enquiries in respect of the Postponed EGM.

9. Shareholders of the Company whose names appear on the register of members of the Company on Thursday, November 26, 2026 will be entitled to attend and vote at the Postponed EGM or any adjourned meetings.

10. All times set out in this supplemental notice refer to Hong Kong local time.

As at the date of this supplemental notice, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.